Table 1 Characteristics of the 41 patients with PsA and obesity included in the study
Number (%) or median (IQR) | |
|---|---|
Sex women/men, n (%) | 26 (63.4)/15 (36.6) |
Age, years | 54 (48.5–62) |
Duration of psoriasis, years | 32 (19–40) |
Duration of PsA symptoms, years | 17 (11–27) |
PsA type, n (%) | |
Peripheral disease | 35 (85) |
Axial disease | 2 (5) |
Combination peripheral/axial | 4 (10) |
History of dactylitis, n (%) | 21 (51) |
History of anterior uveitis, n (%) | 3 (7) |
NSAIDs, n (%) | 27 (66) |
TNFi all, n (%) | 15 (37) |
TNFi in monotherapy | 4 |
TNFi + csDMARD | 11 |
Ustekinumab monotherapy, n (%) | 1 (2.4) |
csDMARD without biologic, n (%) | 19 (46) |
Methotrexate | 13 |
Sulfasalazine | 2 |
Apremilast | 1 |
Methotrexate + sulfasalazine | 3 |
Anti-hypertensives, n (%) | 18 (44) |
Lipid lowering therapy, n (%) | 6 (15) |
Oral anti-diabetics, n (%) | 1 (2.4) |